Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
33 hedge funds and large institutions have $5.25M invested in Acura Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
18% more funds holding
Funds holding: 28 → 33 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
41% less capital invested
Capital invested by funds: $8.96M → $5.25M (-$3.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIL
Rothschild Investment LLC
Chicago,
Illinois
|
+$55.3K |
| 2 |
Renaissance Technologies
New York
|
+$25.8K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$12K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.7K |
| 5 |
Goldman Sachs
New York
|
+$9.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.1K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$12.9K |
| 3 |
CA
Cortland Associates
St Louis,
Missouri
|
-$9.68K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$6.34K |
| 5 |
Morgan Stanley
New York
|
-$4.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| $3K | -$4.02K | -1,454 | -49% |
|
|
BIM
27
BlackRock Investment Management
Wilmington,
Delaware
| $2K | – | – | – |
|
|
28
Bank of America
Charlotte,
North Carolina
| $1K | -$6.34K | -2,291 | -85% |
|
|
RC
29
RegentAtlantic Capital
Morristown,
New Jersey
| $675 | +$830 | +300 | New |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$3K | -741 | Closed |
|
32
Group One Trading
Chicago,
Illinois
| – | +$484 | +175 | New |
|
ACUR Hedge Fund Activity: Q4 2014 in Review
33 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q4 2014, worth a combined $5.25M — down 41% from $8.96M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ACUR positions and 3 closed out — a net gain of 6 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Rothschild Investment LLC, opening a new position worth an estimated $55.3K. The largest seller was Vanguard Group, cutting an estimated $15.1K.
- 33 institutional investors held Acura Pharmaceuticals (ACUR) as of Q4 2014, up from 28 in Q3 2014.
- Funds reported $5.25M of Acura Pharmaceuticals stock for Q4 2014, down 41% quarter-over-quarter.
- 9 funds opened new Acura Pharmaceuticals positions in Q4 2014 and 3 closed out, a net change of +6 holders.
- The largest Acura Pharmaceuticals buyer in Q4 2014 was Rothschild Investment LLC, an estimated $55.3K added.
- The largest Acura Pharmaceuticals seller in Q4 2014 was Vanguard Group, an estimated $15.1K sold.
Based on aggregated 13F filings for Q4 2014.